Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Neurol.

Sec. Stroke

This article is part of the Research TopicBrain Cytoprotection for Reperfusion Injury after Acute Ischemic StrokeView all 13 articles

Systemic Inflammation–Based Hematological Indices and 90-Day Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Stroke: A Systematic Review

Provisionally accepted
  • 1North Sichuan Medical College, Nanchong, China
  • 2People's Hospital of Leshan, Leshan, China

The final, formatted version of the article will be published soon.

Background: Acute ischemic stroke (AIS) is one of the leading causes of mortality and long-term disability worldwide. Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) remains the standard treatment for eligible patients; however, considerable inter-individual variability exists in post-treatment functional outcomes. Increasing evidence suggests that systemic inflammation plays a crucial regulatory role in both ischemic injury cascades and reperfusion efficacy. In recent years, several inflammation-based hematological indices derived from complete blood counts—such as the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), inflammation prognostic index (IPI), and pan-immune-inflammation value (PIV)—have been proposed. These indices comprehensively reflect the balance between innate immune activation and adaptive immune suppression and are considered potential prognostic biomarkers. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we systematically searched PubMed, Embase, and Web of Science for English-language studies published between 2015 and 2025 investigating the relationship between inflammation-based hematological indices and functional outcomes in adult AIS patients receiving intravenous rt-PA. Eligible studies were limited to IVT-only cohorts reporting associations between composite inflammatory indices and clinical outcomes. The search strategy was framed using the PICO (Population, Intervention, Comparison, Outcome) approach, and study quality was assessed using the Newcastle–Ottawa Scale (NOS). Results: A total of fifteen observational cohort studies involving approximately 4,000 AIS patients were included. Higher baseline or early values of NLR, SII, SIRI, and PIV were independently associated with unfavorable 90-day functional outcomes, with predictive performance (AUC) generally ranging from 0.70 to 0.80. Several studies further indicated that dynamic changes in inflammatory indices within 24–48 hours after IVT provided stronger prognostic discrimination than baseline measurements, underscoring the clinical value of early immune monitoring during the acute phase of stroke. Conclusion: Systemic inflammation plays a central role in the pathophysiology and therapeutic response of AIS. Composite inflammation-based hematological indices are simple, economical, and reproducible tools that may assist in early risk stratification and individualized prognostic assessment following IVT. Future studies should incorporate dynamic longitudinal monitoring and integrate multimodal clinical and biomarker data within large, multicenter cohorts to improve model precision and enhance translational applicability.

Keywords: Acute ischemic stroke, intravenous thrombolysis, Systemic inflammatory response, composite inflammation indices, Prognostic evaluation

Received: 05 Sep 2025; Accepted: 05 Nov 2025.

Copyright: © 2025 Wang, Huang, Ma and 坤. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Huiying Huang, 7933044@qq.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.